With 0.14 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.19 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $347.11 whereas the lowest price it dropped to was $337.365. The 52-week range on BIO shows that it touched its highest point at $387.99 and its lowest point at $262.12 during that stretch. It currently has a 1-year price target of $399.33. Beta for the stock currently stands at 0.90.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BIO was up-trending over the past week, with a rise of 4.83%, but this was up by 5.80% over a month. Three-month performance surged to 1.52% while six-month performance rose 22.84%. The stock gained 6.96% in the past year, while it has gained 4.83% so far this year. A look at the trailing 12-month EPS for BIO yields -27.33 with Next year EPS estimates of 11.51. For the next quarter, that number is 2.87. This implies an EPS growth rate of -12.69% for this year and 11.93% for next year.
Float and Shares Shorts:
At present, 22.92 million BIO shares are outstanding with a float of 19.17 million shares on hand for trading. On 2024-12-13, short shares totaled 0.55 million, which was 197.0 higher than short shares on 1731628800. In addition to Mr. Norman D. Schwartz as the firm’s Chairman & CEO, Mr. Jonathan P. DiVincenzo serves as its President & COO.
Institutional Ownership:
Through their ownership of 0.87658 of BIO’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, BIO reported revenue of $649729000.0 and operating income of $64466000.0. The EBITDA in the recently reported quarter was $119447000.0 and diluted EPS was $23.34.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BIO since 3 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BIO analysts setting a high price target of 481.0 and a low target of 315.0, the average target price over the next 12 months is 404.33334. Based on these targets, BIO could surge 39.67% to reach the target high and fall by -8.53% to reach the target low. Reaching the average price target will result in a growth of 17.41% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $10.37498 being high and $10.18525 being low. For BIO, this leads to a yearly average estimate of $10.28511.
